At the time of writing, Travere Therapeutics Inc [TVTX] stock is trading at $16.47, down -0.48%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TVTX shares have gain 9.73% over the last week, with a monthly amount glided 8.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup reaffirmed its Buy rating on June 11, 2025, and dropped its price target to $32. On January 10, 2025, Cantor Fitzgerald initiated with a Overweight rating. Wells Fargo upgraded its rating to a Overweight and increased its price target to $27 on October 21, 2024. Scotiabank initiated its recommendation with a Sector Outperform. Guggenheim upgraded its rating to Buy for this stock on September 09, 2024, but kept the price target unchanged to $25. In a note dated March 27, 2024, Guggenheim downgraded an Neutral rating on this stock.
For the past year, the stock price of Travere Therapeutics Inc fluctuated between $7.93 and $25.29. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $16.47 at the most recent close of the market. An investor can expect a potential return of 32.06% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
According to Travere Therapeutics Inc [NASDAQ:TVTX], the company’s sales were 273.53M for trailing twelve months, which represents an 97.54% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.82%, Pretax Profit Margin comes in at -0.83%, and Net Profit Margin reading is -0.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -11.84 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of12.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.28 points at the first support level, and at 16.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.63, and for the 2nd resistance point, it is at 16.78.
Ratios To Look Out For
It is important to note that Travere Therapeutics Inc [NASDAQ:TVTX] has a current ratio of 2.05. As well, the Quick Ratio is 2.03, while the Cash Ratio is 0.34. Considering the valuation of this stock, the price to sales ratio is 5.35, the price to book ratio is 44.55.
Transactions by insiders
Recent insider trading involved Inrig Jula, CHIEF MEDICAL OFFICER, that happened on Jul 01 ’25 when 815.0 shares were sold. CHIEF FINANCIAL OFFICER, Cline Christopher R. completed a deal on May 05 ’25 to sell 1784.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Dube Eric M sold 18924.0 shares on May 05 ’25.
